New pill targets rare gene faults in Hard-to-Treat cancers
NCT ID NCT07394374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called CG001419 in adults with advanced solid tumors that have certain NTRK gene changes. The trial has two parts: first, finding a safe dose and checking for side effects; second, seeing if the drug can shrink tumors. About 42 people will take the drug daily until their disease gets worse. The goal is to learn if CG001419 is safe and effective for these cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CG001419 tablets
- What this could lead to
- If this works, it could offer a new treatment option for people with advanced solid tumors that have specific NTRK gene changes and have run out of standard therapies.
- What could go wrong
- This is an early-phase trial with only 42 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NTRK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanxi Provincial Cancer Hospital
RECRUITINGTaiyuan, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
-
The Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
-
The Sir Run Run Shaw Hospital, Affiliated to Zhejiang University School of Medicine
RECRUITINGHangzhou, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, China
-
Zhejiang Provincial Cancer Hospital
RECRUITINGHangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.